

**Effect of Vitamin D on All-Cause Mortality in Heart Failure (EVITA): A 3-Year
Randomized Clinical Trial with 4,000 IU Vitamin D Daily**

Appendix

Supplemental Table 1: Causes of hospitalization

Supplemental Table 2: Circulating in-study 25-hydroxyvitamin D levels (nmol/L, median and IQR) in patients with baseline 25-hydroxyvitamin D levels <30 nmol/L and ≥30 nmol/L, by treatment group

Supplemental Table 3: Sort of Device Implant

Supplemental Table 4: Characteristics of patients with hypercalcemia

Supplemental Table 1: Causes of hospitalization

Cause	Vitamin D Group (n=199)	Placebo Group (n=201)	P-value
Cardiac, No. (%)	85 (43)	73 (36)	0.220
Non-cardiac, No. (%)	22 (11)	17 (9)	0.404
Planned, No. (%)	8 (4)	12 (6)	0.492
Unknown, No. (%)	10 (5)	10 (5)	>0.99

Supplemental Table 2: Circulating in-study 25-hydroxyvitamin D levels (nmol/L, median and IQR) in patients with baseline 25-hydroxyvitamin D levels <30 nmol/L and ≥30 nmol/L, by treatment group

Parameter	Study Group	t1	t2	t3	t4	t5	t6
Initial 25OHD <30 nmol/L	Vitamin D, No.	81	65	51	46	39	39
	Placebo, No.	56	48	38	37	29	33
	Vitamin D	81 (39-113)	82 (34-112)	82 (55-129)	92 (51-139)	98 (65-118)	83 (52-122)
	Placebo	34 (23-45)	26 (19-40)	37 (25-49)	30 (19-45)	43 (24-59)	35 (23-57)
Initial 25OHD ≥30 nmol/L	Vitamin D, No.	87	69	54	51	47	45
	Placebo, No.	101	87	75	61	51	55
	Vitamin D	113 (82-139)	104 (71-134)	109 (88-148)	111 (75-150)	121 (93-159)	108 (69-146)
	Placebo	48 (33-68)	44 (35-56)	45 (35-58)	43 (33-53)	45 (35-52)	41 (33-60)

t1-t6, study month 6,12,18,24,30, and 36

Supplemental Table 3: Sort of Device Implant

System	Vitamin D Group (n=28)	Placebo Group (n=15)
Extracorporeal circulatory membrane oxygenation, No. (%)	4 (14)	2 (13)
Left ventricular Assist Device, No. (%)	22 (79)	11 (73)
Biventricular Assist Device, No. (%)	2 (7)	1 (7)
Total Artificial Heart, No. (%)	0 (0)	1 (7)

Supplemental Table 4: Characteristics of patients with hypercalcemia

Age (years)	Sex	Study Group	Follow-up visit	Plasma Calcium (mmol/L)	25OHD (nmol/L)	Date of measurement	Baseline eGFR (ml/min/1.73m ²)	Plasma calcium after study exclusion (mmol/L)	Date of calcium measurement after study exclusion	Deceased within study duration	Deceased after study duration	Date of death
49	Female	Placebo	6-month	2.79	59.0	10/17/11	42	2.33	04/10/12	No	Yes ¹	08/02/14
60	Male	Vitamin D	6-month	2.81	90.7	10/10/13	55	-	-	No	Yes ¹	11/10/16
26	Female	Vitamin D	12-month	2.83	138.5	11/11/13	95	2.52	05/23/14	No	No	
71	Male	Vitamin D	12-month	2.78	117.6	12/07/11	58	2.71	07/23/12	No	Yes ¹	09/08/14
41	Male	Vitamin D	12-month	2.94	193.2	06/03/14 (10:30 am)	25	2.44	06/03/14 (9:00 pm)	No	No	
55	Female	Vitamin D	12-month	2.78	92.9	02/28/12	55	2.71	10/22/12	No	Yes ¹	12/24/15
56	Female	Vitamin D	18-month	2.81	119.1	01/16/13	45	2.59	04/02/15	No	Yes ²	07/30/15
30	Female	Placebo	18-month	3.05	49.4	09/05/15	51	2.44	06/03/15	No	No	
51	Male	Placebo	24-month	2.84	34.7	06/13/13	37	-	-	No	No	
61	Male	Placebo	24-month	3.20	31.2	04/11/13	44	2.53	06/21/13	No	Yes ³	10/01/14
50	Male	Vitamin D	30-month	2.90	122.1	05/20/14	42	2.34	09/10/16	No	No	
51	Female	Vitamin D	30-month	2.99	158.5	07/21/14	55	2.64	22.09.2014	No	Yes ⁴	08/19/15
62	Male	Vitamin D	30-month	2.81	159.0	07/30/14	43	2.62	03.12.2014	No	No	
57	Male	Vitamin D	36-month	2.76	126.8	03/18/14	81	-	-	No	No	
54	Female	Placebo	36-month	2.81	29.0	10/14/13	83	-	-	No	No	

-no data available; cause of death: ¹unknown; ²multiple organ failure; ³intracerebral bleeding; ⁴sepsis